Market Cap (In CAD)
49.02 Million
Revenue (In CAD)
-
Net Income (In CAD)
-9.26 Million
Avg. Volume
2639.00
- Currency
- CAD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 0.5-1.35
- PE
- -
- EPS
- -
- Beta Value
- -0.845
- ISIN
- CA4229101098
- CUSIP
- 422910109
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Jacek Antas
- Employee Count
- -
- Website
- https://www.helixbiopharma.com
- Ipo Date
- 1996-08-13
- Details
- Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with ProMab Biotechnologies, Inc. to develop novel antibody and chimeric antigen receptor T-cell therapy to treat multiple myeloma, as well as a license agreements with Xisle Pharma Ventures Trust and National Research of Council Canada. The company is headquartered in Richmond Hill, Canada.
More Stocks
-
AILLOAmeren Illinois Company
AILLO
-
WARDINMOBIWARDWIZARD INNOVATIONS AND MOB
WARDINMOBI
-
605259Lutian Machinery Co., Ltd.
605259
-
6055
-
688232
-
600831
-
DTATFData#3 Limited
DTATF
-
3576